<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01938105</url>
  </required_header>
  <id_info>
    <org_study_id>WJPMF-2013-428-2081</org_study_id>
    <nct_id>NCT01938105</nct_id>
  </id_info>
  <brief_title>Preoperative Chemoradiotherapy Combined With Nimotuzumab for Cervical Cancer</brief_title>
  <official_title>Preoperative Concurrent Chemoradiotherapy Combined With Nimotuzumab Injection for Locally Advanced Cervical Cancer: a Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>People's Hospital of Guangxi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wu Jieping Medical Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>People's Hospital of Guangxi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the feasibility and efficacy of preoperative
      nimotuzumab injection combined with concurrent chemoradiotherapy for initially inoperable,
      locally advanced cervical cancer.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment related toxicities</measure>
    <time_frame>at 1 year</time_frame>
    <description>Acute and chronic toxicities.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor response after preoperative treatment</measure>
    <time_frame>assessed at 4-5 weeks after the completion of preoperative treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>at 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>at 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Locally Advanced Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>Nimotuzumab+chemoradiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Nimotuzumab+chemoradiotherapy</intervention_name>
    <description>Nimotuzumab 200mg per week will be administered concurrent with platinum-based chemotherapy and intensity-modulated radiation therapy. After the preoperative treatment, patients will be assessed for tumor response and operability. For those who are considered to be candidates for operation, radical surgery will be performed.</description>
    <arm_group_label>Nimotuzumab+chemoradiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically proven squamous cell cervical cancer

          -  Stages IB2-IIIB according to FIGO Staging System

          -  Age:18-75

          -  ECOGï¼œ2

          -  Normal bone marrow function

          -  Initial assessed and considered not candidates for operation

          -  Signed study-specific consent form

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Patients with other malignancies

          -  Patients who received radiotherapy or chemotherapy previously

          -  Presence of uncontrolled life-threatening illness

          -  Allergy to platinum or monoclonal antibody
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heming Lu, MS</last_name>
    <role>Study Chair</role>
    <affiliation>People's Hospital of Guangxi</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Heming Lu, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>People's Hospital of Guangxi</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yun Mo, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>People's Hospital of Guangxi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heming Lu, MS</last_name>
    <phone>+86-771-218-6503</phone>
    <email>gxheminglu@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>People's Hospital of Guangxi Zhuang Autonomous Region</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heming Lu, MS</last_name>
      <phone>+86-771-218-6503</phone>
      <email>gxheminglu@sina.com</email>
    </contact>
    <investigator>
      <last_name>Heming Lu, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yun Mo, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 4, 2013</study_first_submitted>
  <study_first_submitted_qc>September 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2013</study_first_posted>
  <last_update_submitted>September 24, 2013</last_update_submitted>
  <last_update_submitted_qc>September 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>People's Hospital of Guangxi</investigator_affiliation>
    <investigator_full_name>Heming Lu</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Cervical cancer</keyword>
  <keyword>Nimotuzumab</keyword>
  <keyword>Intensity-modulated radiation therapy</keyword>
  <keyword>Concurrent chemoradiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

